Pharmaceutical News

RSS

Study reveals why long-term use of L-DOPA leads to dyskinesia

Researchers have discovered why long-term use of L-DOPA (levodopa), the most effective treatment for Parkinson's disease, commonly leads to a movement problem called dyskinesia, a side effect that can be as debilitating as Parkinson's disease itself.

11 Sep 2015

Molecular Health enters into license agreement to supply SafetyMAP software to FDA

Molecular Health has entered into a commercial license to provide the FDA with use of its SafetyMAP software - formally known as Molecular Analysis of Side Effect information (MASE), to provide a comprehensive and dynamic analytical solution for the detection and molecular analysis of drug-induced adverse events for all marketed drugs and for predicting safety issues of new drug candidates.

11 Sep 2015

Old prescription medicines may cause more harm than good

Many of us are guilty of neglecting our medicine cabinet - specifically, our prescriptions. Sometimes we feel the need to hang onto them, perhaps because they were costly or "just in case."

10 Sep 2015

CureVac, IAVI team up to advance development, testing of AIDS vaccines

The non-profit International AIDS Vaccine Initiative (IAVI) and biopharmaceutical company CureVac are partnering to accelerate the development of AIDS vaccines, utilizing novel immunogens developed by IAVI and partners, delivered via CureVac's novel messenger RNA (mRNA) technology.

10 Sep 2015

CureVac announces official launch of U.S. operations in Cambridge, MA

CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announced the official launch of its U.S. operations in Cambridge, MA, as the company advances the development of its proprietary mRNA platform technology and multiple, clinical-stage mRNA therapeutics and vaccines.

10 Sep 2015

New systematic review questions effectiveness of MVA85A vaccine on TB

A new systematic review of animal studies testing a vaccine for tuberculosis raises questions about whether the studies provided sufficient evidence to move into trials of children.

10 Sep 2015

Comprehensive review looks at safety, efficacy of treatment options for premenstrual dysphoric disorder

Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome that causes major disruption in several areas of life for many women. Many treatment options have been proposed, but which are most effective? A comprehensive review of the evidence, including specific treatment guidelines, is presented in the September Journal of Psychiatric Practice, published by Wolters Kluwer.

9 Sep 2015

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing and commercializing innovative pain treatments, today announced the launch of OXAYDO (oxycodone HCI, USP) tablets -CII in the United States.

9 Sep 2015

New study reveals effect of diabetes drug on bone health, benefit of exercise in mice

Inside our bones there is fat. Diabetes increases the amount of this marrow fat. And now a study from the UNC School of Medicine shows how some diabetes drugs substantially increase bone fat and thus the risk of bone fractures.

9 Sep 2015

AfPA’s video highlights new technology and pill formulations that deter individuals from abusing opioids

Today the Alliance for Patient Access released a new white board video, "A Prescription for Reducing Opioid Abuse." The video, released to coincide with National Pain Awareness Month, highlights new technology and innovative pill formulations that deter individuals from abusing opioids.

9 Sep 2015

Daily iron supplementation during pregnancy does not increase malaria risk in malaria-endemic region

Among women in a malaria-endemic region in Kenya, daily iron supplementation during pregnancy did not result in an increased risk of malaria, according to a study in the September 8 issue of JAMA. Iron supplementation did result in increased birth weight, gestational duration, neonatal length, and a decreased risk of low birth weight and prematurity.

9 Sep 2015

Vernalis Therapeutics announces availability of codeine-based cough and cold syrup in the U.S.

Vernalis Therapeutics Inc., a subsidiary of Vernalis plc, today announced that Tuzistra XR (codeine polistirex and chlorpheniramine polistirex), extended-release oral suspension, CIII (DEA Schedule III) is now available to adult patients and physicians in the United States.

8 Sep 2015

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of an exclusive worldwide license agreement to further develop and commercialize DT2219ARL, a novel therapy for the treatment of various human B cell cancers, leukemias and lymphomas.

8 Sep 2015

FDA grants Orphan Drug designation to Rigel's Fostamatinib for treatment of patients with ITP

Rigel Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug designation to Fostamatinib, Rigel's oral spleen tyrosine kinase (SYK) inhibitor which is currently in Phase 3 clinical studies in patients with chronic immune thrombocytopenic purpura (ITP).

8 Sep 2015

Mylan releases generic version of Yasmin Tablets in the U.S.

Mylan N.V. today announced the U.S. launch of Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/0.03 mg, which is the generic version of Bayer's Yasmin Tablets. Mylan's partner Famy Care Ltd. received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for use by women to prevent pregnancy.

8 Sep 2015

Helsinn, BIAL sign exclusive distribution and licence agreement for Anamorelin

Helsinn, the Swiss Group focused on building quality cancer care, and BIAL - Portela & Ca. S.A., one of the largest Iberian pharmaceutical companies, today announce that they have entered into an agreement for the exclusive distribution and licence rights to Anamorelin in Spain, Portugal, Angola and Mozambique.

8 Sep 2015

Early antiviral treatment reduces disability risk, hospitalization time in older people

Early treatment of flu-hospitalized people 65 and older with flu antiviral medications cuts the duration of their hospital stay and reduces their risk of needing extended care after discharge, a new CDC study finds.

4 Sep 2015

TXA drug reduces blood transfusion, saves costs

Using an inexpensive drug for every hip or knee replacement since 2013 has helped St. Michael's Hospital reduce its number of red blood cell transfusions performed during these surgeries by more than 40 per cent without negatively affecting patients, according to new research.

4 Sep 2015

Researchers one step closer to developing asthma vaccine

Researchers at VIB (a leading life sciences institute in Flanders, Belgium) and Ghent University have successfully established a causal relationship between exposure to so-called farm dust and protection against asthma and allergies.

4 Sep 2015

Cipla enters into definitive agreements to acquire two US-based companies

Cipla, a global pharmaceutical company which uses technology and innovation to meet the everyday needs of all patients, today announced that its UK arm, Cipla EU has entered into definitive agreements to acquire two US-based companies, InvaGen Pharmaceuticals Inc., and Exelan Pharmaceuticals Inc.

4 Sep 2015

Pharmaceutical News

Study reveals why long-term use of L-DOPA leads to dyskinesia

Molecular Health enters into license agreement to supply SafetyMAP software to FDA

Old prescription medicines may cause more harm than good

CureVac, IAVI team up to advance development, testing of AIDS vaccines

CureVac announces official launch of U.S. operations in Cambridge, MA

New systematic review questions effectiveness of MVA85A vaccine on TB

Comprehensive review looks at safety, efficacy of treatment options for premenstrual dysphoric disorder

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

New study reveals effect of diabetes drug on bone health, benefit of exercise in mice

AfPA’s video highlights new technology and pill formulations that deter individuals from abusing opioids

Daily iron supplementation during pregnancy does not increase malaria risk in malaria-endemic region

Vernalis Therapeutics announces availability of codeine-based cough and cold syrup in the U.S.

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

FDA grants Orphan Drug designation to Rigel's Fostamatinib for treatment of patients with ITP

Mylan releases generic version of Yasmin Tablets in the U.S.

Helsinn, BIAL sign exclusive distribution and licence agreement for Anamorelin

Early antiviral treatment reduces disability risk, hospitalization time in older people

TXA drug reduces blood transfusion, saves costs

Researchers one step closer to developing asthma vaccine

Cipla enters into definitive agreements to acquire two US-based companies

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News